Gout Author: Grace P. Teal, MD; Howard A. Fuchs, MD
Editorial changes - 2009-09-02
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools
Consultation for Management
  • Refer patients with onset of gout at a very early age to a specialist.
  • Consider that patients with poorly controlled gout may benefit from consultation with a specialist.
  • Consider consultation with a rheumatologist for help in managing patients with gout superimposed on other types of arthritis.


Refer patients with onset of gout at a very early age to a specialist. C

  • Refer patients with onset of documented gout before 20 years of age to a specialist in rheumatology or inherited metabolic diseases.
Background | Back to top


Consider that patients with poorly controlled gout may benefit from consultation with a specialist. C

  • Consider consultation with a rheumatologist in complex patients with presumed gout for:
    • Help in confirming the accuracy of the diagnosis
    • Management of recurrent acute gouty attacks
    • Choice of uric acid-lowering therapy
    • Management of other concurrent arthritides
  • Consider consultation with a nephrologist for help in managing patients with renal inufficiency or urate nephropathy and its implications for drug therapy.
Background | Back to top


Consider consultation with a rheumatologist for help in managing patients with gout superimposed on other types of arthritis. C

  • Refer patients with gout and other concomitant inflammatory arthritides, such as rheumatoid arthritis, systemic lupus, and psoriatic arthritis, to a rheumatologist for management.
Background | Back to top

FAQs
Grace P. Teal, MD (deceased) has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Howard A. Fuchs, MD, is a consultant for TAP Pharmaceuticals.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.